Updated on 29 September 2016
Singapore: Germany based developer of cardio and endovascular medical technology, BIOTRONIK, has launched a new manufacturing facility in Singapore to manufacture hybrid drug-eluting coronary stent and pacemaker.
The new site includes a 1500 m² ISO class 7 cleanroom, supplying the global market with products for the company's vascular intervention and cardiac rhythm management businesses. The facility will develop Orsiro, a hybrid drug-eluting coronary stent, along with Solia pacemaker leads.
"Singapore's skilled workforce, excellent infrastructure and favorable business environment made it a natural choice for BIOTRONIK as we seek to expand our global footprint," said Erik Trip, Managing Director, Asia Pacific Manufacturing, BIOTRONIK.
"We are building a professional team at the new site and will eventually create hundreds of new jobs in this exciting industry. This investment will support BIOTRONIK's dynamic growth, both in the Asia Pacific region and globally."
The company plans to create over 200 jobs for highly-trained operators and professionals in R&D and senior leadership roles, investing more than SGD 30 million into operations in the country over the next few years.
"We welcome BIOTRONIK's decision to establish its Asia Pacific manufacturing facility in Singapore. This is testament to our strong manufacturing workforce, high quality standards, and deep science and engineering capabilities, which are important in the production of implantable cardiovascular devices," said Weng Si Ho, Director, Biomedical Sciences, Singapore Economic Development Board (EDB). "Asia continues to provide an exciting growth opportunity for global medical device companies. We are confident that Singapore will continue to grow as a global medical technology hub, which will enable further economic growth and good jobs created here."
Besides Singapore, BIOTRONIK has manufacturing hubs in US, Germany and Switzerland to develop implantable pacemakers, defibrillators and stent therapy.